Tmt212

Other Medications

EU Experimental ES Not available 1 Clinical Trials

Description

Tmt212 is an investigational medication currently being studied by Novartis Pharmaceuticals. It is being evaluated in clinical trials, including one for colorectal cancer (CRC). The trials are in early phases (Phase 1), meaning they primarily focus on determining the safety and appropriate dosage of the drug, as well as looking for early signs of effectiveness. Tmt212 is often studied in combination with other experimental or approved therapies. The specific role of Tmt212 in treating CRC and its effectiveness are still under investigation.

Mechanism of Action

The specific way Tmt212 works (its mechanism of action) is being investigated in clinical trials. It is being studied in combination with other agents like PDR001, CJM112, EGF816, and canakinumab (Ilaris®) or trametinib (Mekinist®). The goal is to understand how Tmt212 interacts with these other drugs and affects the body, particularly in relation to cancer cells.

Side Effects

As Tmt212 is an investigational drug in early-phase trials Detailed information about its side effects is still being gathered. The safety and tolerability of Tmt212 are key focuses of the ongoing clinical trials. Specific side effects will be determined as more patients are treated and data is collected.

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials

NCT02900664 Phase 1
Archived
A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)
United States, Belgium, Canada, France, Israel, Italy, Singapore, Spain, Taiwan

Quick Info

CategoryOther Medications
EU EMA StatusExperimental
ES Spain AccessNot available
Clinical Trials1
View Clinical Trials Back to Drug Glossary

Related Medications

Uracil
Other Medications
771 trials
Leucovorin
Other Medications
631 trials
Trifluridine
Other Medications
45 trials
Paclitaxel
Other Medications
43 trials
Cyclophosphamid
Other Medications
40 trials
Cyclophosphamide
Other Medications
39 trials

Medical Disclaimer

This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.